CEBPA and Hepatic fibrosis: In addition, increased p-C/EBPα-S193 augments the C/EBPα-HDAC1 complex in aged liver under CCl4 treatment, which directly represses the promoters of Cebpα, Farnesoid X receptor (Fxr), and telomere reverse transcriptase (Tert) genes and disrupts the Rb-E2F1 complex, leading to increased apoptosis, accelerated liver cell proliferation (including HSCs), and the early development of liver fibrosis [73].